Login to Your Account

Positive Phase III Results May Mean Big Payday for Ariad

By Catherine Shaffer

Wednesday, January 19, 2011

Top-line results from a Phase III trial showed that Ariad Pharmaceuticals Inc.'s ridaforolimus has promise as a treatment for metastatic soft-tissue or bone sarcoma. In the trial designated SUCCEED, carried out under a special protocol assessment granted by the FDA, there was a 28 percent reduction in the risk of progression compared to placebo, and a 21 percent (or 3.1 week) improvement in progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription